Auto Added by WPeMatico
Neko Health has raised $700 million to expand its AI body scans in the United States, starting with a clinic in New York. The company’s preventive screening service combines medical imaging, blood tests, proprietary sensors, and clinician review. The Series C round was led by Lightspeed Venture Partners and co-led by O.G. Venture Partners. Existing […]
Neko Health raises $700 million to expand AI body scans in the US Read More »
AWS (Amazon Web Services) has explained how Bluesight developed Prism, an AI layer that connects hospital pharmacy and compliance data across its product suite. Prism Assistant for ControlCheck has reached general availability and operates across 20 health systems, according to AWS vendor statements. Meanwhile, a multi-product agent for 340B Group Purchasing Organisation (GPO) compliance remains
AWS and Bluesight build AI for hospital 340B compliance Read More »
AI agent crawlers, the bots that fetch pages in real time on behalf of a person waiting for an answer, will be blocked by default on a slice of the web from September 15 onwards. Cloudflare announced the change on July 1, and most of the coverage since then has focused on Google. The more useful part
AI agent crawlers now need permission. Here’s how to get it Read More »
A recent AWS GraphRAG deployment reduced drug research and development cycles in pharmaceutical environments by 87 percent. This acceleration is achieved by integrating previously separated proprietary databases into a unified and queryable knowledge graph. Historically, initial data gathering and screening phases took over six months per iteration, yielding a low five percent success rate. Crucial
AWS GraphRAG deployment cuts drug research cycles by 87% Read More »
Several NHS hospitals are preparing to use an AI-powered blood test to help assess women referred for possible womb cancer before invasive checks are carried out. According to The Guardian, around 90,000 postmenopausal women in England are referred by GPs each year for checks after experiencing heavy bleeding. About 10,000 women are diagnosed with womb
NHS AI blood test could reduce invasive womb cancer checks Read More »
Insilico Medicine is advancing to Phase III human trials for testing a drug identified by AI targeting idiopathic pulmonary fibrosis (IPF). This progression supplies the computational drug discovery sector with empirical test cases, advancing an AI medicine past early safety evaluations into late-stage efficacy validation. IPF destroys respiratory capacity through severe lung tissue scarring. Patients
Insilico Medicine advances AI drug for IPF to Phase III trials Read More »
L’Oreal is using AI to shorten product development timelines and identify new uses for ingredients already present in its portfolio. The French cosmetics group has applied AI in its laboratories for the past four years, with Fabrice Megarbane, president of L’Oreal’s consumer products division, telling Reuters that the technology helps the company predict how molecules
L’Oreal, Mondelez, and Nestle use AI to speed product development Read More »
An AI companion sounds dystopian, but it has become a common thread in the wider conversation about the perils of generative AI. What it refers to is essentially a conversational agent built to sustain an ongoing, personal relationship with a user, with the memory and steady persona that keep it consistent from one session to
China’s AI companion rules: what Beijing is really going after Read More »
Takeda has entered a strategic collaboration with Hong Kong-based Insilico Medicine to use AI in early-stage drug discovery across the Japanese pharmaceutical company’s therapeutic areas. The companies did not disclose which therapeutic areas or disease targets will be covered under the collaboration. The agreement gives Takeda access to Insilico’s Pharma.AI platform, which supports biological target
Takeda signs US$600M AI drug discovery deal with Insilico Read More »
Anthropic Claude Science now integrates the NVIDIA BioNeMo Agent Toolkit to accelerate computational life sciences research. Anthropic has launched the public beta of Claude Science, an AI workbench built for scientific research. The platform enables scientists to converse directly with digital agents using natural language to execute end-to-end research workflows. This system connects natively to
NVIDIA BioNeMo accelerates Anthropic Claude Science Read More »
